Status:
COMPLETED
Efficacy and Safety of NovoMix® 30 in Subjects With Type 2 Diabetes
Lead Sponsor:
Novo Nordisk A/S
Conditions:
Diabetes
Diabetes Mellitus, Type 2
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
This trial is conducted in Europe. The aim of this trial is to investigate the efficacy and safety of biphasic insulin aspart (NovoMix®30) to that of biphasic human insulin (Mixtard® 30) in subjects w...
Eligibility Criteria
Inclusion
- Type 2 diabetes for at least 24 months
- Insulin treatment for the pase 3 months
- HbA1c (glycosylated haemoglobin) below 13%
- BMI (Body Mass Index) below 40 kg/m\^2
- Ability and willingness to perform self-blood glucose monitoring
Exclusion
- Receipt of any investigational drug within 4 weeks prior to this trial
- Treatment of OHAs (Oral Hypoglycaemic Agents) within 4 weeks prior to this trial
- Total daily insulin dosage less than or equal to 1.8 IU/kg
Key Trial Info
Start Date :
August 19 2002
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 15 2003
Estimated Enrollment :
292 Patients enrolled
Trial Details
Trial ID
NCT01467401
Start Date
August 19 2002
End Date
May 15 2003
Last Update
February 24 2017
Active Locations (57)
Enter a location and click search to find clinical trials sorted by distance.
1
Novo Nordisk Investigational Site
Århus C, Denmark, 8000
2
Novo Nordisk Investigational Site
Esbjerg, Denmark, 6700
3
Novo Nordisk Investigational Site
Herning, Denmark, 7400
4
Novo Nordisk Investigational Site
Holbæk, Denmark, 4300